## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG 1.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams**
- Source: Business Wire | 20251216T130850 | Bullish | Relevance: 100%
- Hologic, Inc. announced new data showing its AI-powered mammography solution, Genius AI Detection, helped identify breast cancers initially missed in a study of 7,500 screening exams. The AI system flagged approximately one-third of false-negative cases and nearly 90% of previously identified cancers, accurately localizing suspicious areas. This study highlights AI's potential to improve breast cancer detection, especially for invasive ductal carcinomas.

**2. Hologic stock hits 52-week high at $75.14 By Investing.com**
- Source: Investing.com Australia | 20251215T150019 | Bullish | Relevance: 100%
- Hologic Inc (HOLX) stock recently hit a 52-week high of $75.14, marking a 3.67% increase over the past year. The medical technology company demonstrates strong financial health with moderate debt, an impressive Altman Z-Score, and low price volatility, trading slightly below its Fair Value according to InvestingPro. Recent news also highlights strong Q4 2025 results, expanded CE marking for its Genius Digital Diagnostics System in the EU, and upcoming presentations on its Breast Cancer Index Test.

**3. Hologic's BCI test shows growing impact in endocrine therapy decisions**
- Source: MSN | 20251214T091945 | Bullish | Relevance: 100%
- The article highlights the increasing influence of Hologic's Breast Cancer Index (BCI) test on endocrine therapy decisions. This suggests that the BCI test is gaining recognition as a valuable tool for guiding treatment strategies in breast cancer patients.

**4. Hologic’s AI mammography tech flags previously missed breast cancers By Investing.com**
- Source: Investing.com Nigeria | 20251216T190837 | Bullish | Relevance: 100%
- Hologic, Inc. (NASDAQ:HOLX) announced new data showing its Genius AI Detection solution identified approximately one-third of previously missed breast cancers in a retrospective analysis. The AI system also flagged nearly 90% of previously identified breast cancer cases by radiologists, demonstrating significant potential for improving early detection. This innovation supports Hologic's strong financial performance, with the company reporting annual revenue of $4.1 billion.

**5. Hologic’s AI mammography tech flags previously missed breast cancers By Investing.com**
- Source: Investing.com Australia | 20251216T135541 | Bullish | Relevance: 100%
- Hologic, Inc. announced that its Genius AI Detection solution identified approximately one-third of previously missed breast cancers in a retrospective analysis. The AI system also accurately localized nearly 90% of previously identified breast cancer cases. This innovation contributes to Hologic's strong financial performance, with the company reporting annual revenue of $4.1 billion.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.66 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.66 |
| Forward P/E | 15.0 |
| Current P/E | 16.5 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.2% to 0.4% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.43% (CS: 46) | Neutral |
| RSI_14 | 64.6 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.142x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.02
- **Stop Loss:** $74.30 (1.0% risk)
- **Target:** $75.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1388
- **Position Value:** $104,127.76
- **Portfolio %:** 104.13%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*